Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joel Lewis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Beta
- 0.38
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -51.85
Financials
Net Income
$-3.53MEBITDA
$-2.71MFree Cash Flow
$-2.27MEPS (diluted)
$-0.04Shares Outstanding (diluted)
89.62M+177.4%Operating Expenses
$3.37MCash & Debt
$11.71MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-30.84M | $-0.48 |
| 2024 | $0.00 | $-47.05M | $-0.76 |
| 2023 | $0.00 | $-41.07M | $-0.74 |
| 2022 | $0.00 | $-38.78M | $-0.65 |
| 2021 | $0.00 | $-30.53M | $-0.52 |
| 2020 | $0.00 | $-23.46M | $-0.41 |
| 2019 | $0.00 | $-13.29M | $-0.39 |
| 2018 | $0.00 | $-13.90M | $-0.35 |
| 2017 | $0.00 | $-16.23M | $-0.46 |
| 2016 | $0.00 | $-21.44M | $-0.73 |
| 2015 | $0.00 | $-20.03M | $-0.83 |
| 2014 | $0.00 | $-15.79M | $-0.72 |
| 2013 | $0.00 | $-12.09M | $-0.72 |
| 2012 | $0.00 | $-9.68M | $-0.64 |
Valuation
GALThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (5)
- Newszacks.com·3d ago·Negative
Galectin Therapeutics (GALT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Galectin Therapeutics (GALT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·4d ago·Positive
All You Need to Know About Galectin Therapeutics (GALT) Rating Upgrade to Buy Galectin Therapeutics (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
…American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninva…
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-0.03 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.04 vs $-0.05beat
- Fri, Aug 14$-0.14 vs $-0.09miss
- Fri, May 15$-0.08 vs $-0.06miss
- Tue, Mar 31$-0.08 vs $-0.10beat
- Fri, Nov 14$-0.13 vs $-0.11miss
- Thu, Aug 14$-0.12 vs $-0.16beat
Estimates and results for GALT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GALT officers and directors.
- Bought
- $23k
- Sold
- $2.0m
3 trades
24 trades
- Jamil Khurramsold
- Shlevin Harold H.sold
- Jamil Khurramsold
- Shlevin Harold H.sold
- Jamil Khurramsold
- Jamil Khurramsold
- Jamil Khurramsold
- Eldred Karybought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GALT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
